her2 biosimilars in clinical practice - an interview with dr. william gradishar.mp4
Published 8 years ago • 44 plays • Length 3:01Download video MP4
Download video MP3
Similar videos
-
2:55
her2 biosimilars in clinical practice - an interview with dr. william gradishar
-
5:21
mechanisms and implications of her2 resistance - an interview with dr. william gradishar.mp4
-
5:15
mechanisms and implications of her2 resistance - an interview with dr. william gradishar
-
7:40
practical considerations in integrating her2 biosimilars in clinical practice
-
7:46
practical considerations in integrating her2 biosimilars in clinical practice
-
4:34
her2 cancer treatment - resistance, immunologic implications, and biosimilars.mp4
-
4:37
combating 'financial toxicity' - her2 biosimilars and combinations with chemotherapy.mp4
-
8:10
management of her2 cancers - integrating new data into clinical practice.mp4
-
5:05
anti-her2 mechanisms of approved her2 inhibitors
-
20:11
her2-positive breast cancer—reduce your risk of recurrence | access health
-
4:33
the her pathway and cancer
-
5:05
current advances and research in breast cancer - an overview.mp4
-
55:48
new & supporting data for optimizing therapy in her2 breast cancer | dr. bagegni & dr. gradishar
-
4:27
study of immunotherapy combinations for patients with her2-positive metastatic breast cancer
-
0:50
dr. gradishar discusses dual her2-targeting in breast cancer
-
5:13
targeting her2 in breast cancer patients with brain metastases
-
3:39
biosimilars for her2-targeted antibodies
-
3:39
biosimilars for her2-targeted antibodies
-
6:05
her2 study
-
5:09
the use of biosimilars in her2 breast cancer
-
1:50
findings of a biosimilar trastuzumab study in patients with her2-positive breast cancer
-
1:00
dr. slamon on the use of trastuzumab and bevacizumab biosimilars in breast cancer